Federated Hermes Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL

Federated Hermes Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 55,929.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 126,066 shares of the medical research company’s stock after acquiring an additional 125,841 shares during the period. Federated Hermes Inc. owned 0.26% of Charles River Laboratories International worth $19,128,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Brown Advisory Inc. grew its holdings in shares of Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after buying an additional 114 shares in the last quarter. Amundi boosted its holdings in shares of Charles River Laboratories International by 1,284.1% during the second quarter. Amundi now owns 226,257 shares of the medical research company’s stock worth $35,633,000 after purchasing an additional 209,910 shares during the last quarter. Epoch Investment Partners Inc. purchased a new stake in shares of Charles River Laboratories International in the second quarter valued at $580,000. Invesco Ltd. grew its position in shares of Charles River Laboratories International by 11.6% in the second quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after purchasing an additional 128,785 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Charles River Laboratories International by 63.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 578,609 shares of the medical research company’s stock valued at $87,792,000 after purchasing an additional 225,027 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on CRL shares. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their target price for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Baird R W raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Argus set a $200.00 price target on shares of Charles River Laboratories International in a research note on Monday, November 17th. Finally, Mizuho boosted their price objective on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $190.86.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $194.65 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The company has a market cap of $9.58 billion, a PE ratio of -124.78, a P/E/G ratio of 6.57 and a beta of 1.63. The company’s fifty day simple moving average is $176.72 and its 200-day simple moving average is $162.69. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $200.10.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. During the same period in the prior year, the firm earned $2.59 EPS. The firm’s quarterly revenue was down .5% compared to the same quarter last year. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).